S. Gustavson

发表

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Neha J. Pagidipati, R. Holman, A. Gray, 2019, Diabetes Care.

Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Neha J. Pagidipati, B. Zinman, R. Holman, 2017, The New England journal of medicine.

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

R. Holman, Adrian F. Hernandez, H. Heerspink, 2019, Cardiovascular Diabetology.

Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog.

P. Flakoll, E. Donahue, C. Chu, 2004, Metabolism: clinical and experimental.

Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog.

P. Flakoll, E. Donahue, C. Chu, 2003, American journal of physiology. Endocrinology and metabolism.

Non‐linear increase in GLP‐1 levels in response to DPP‐IV inhibition in healthy adult subjects

B. Hirshberg, G. Preston, S. Gustavson, 2008, Diabetes, obesity & metabolism.

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

R. Holman, Adrian F. Hernandez, J. Buse, 2019, Diabetes Care.

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial

Neha J. Pagidipati, R. Holman, J. Chan, 2018, Journal of the American Heart Association.

Islet Auto‐Transplantation into an Omental or Splenic Site Results in a Normal Beta Cell but Abnormal Alpha Cell Response to Mild Non‐Insulin‐Induced Hypoglycemia

D. Hunkeler, J. Lakey, R. Rajotte, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes

R. Holman, S. Stevens, Adrian F. Hernandez, 2020, Circulation.

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.

A. Cherrington, D. Neal, M. Shiota, 2003, American journal of physiology. Endocrinology and metabolism.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Neha J. Pagidipati, B. Zinman, R. Holman, 2017, American heart journal.

Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion.

P. Flakoll, E. Donahue, S. Vaughan, 2003, American journal of physiology. Endocrinology and metabolism.

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Adrian F Hernandez, Robert J Mentz, Nayyar Iqbal, 2017, The lancet. Diabetes & endocrinology.

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.

R. Holman, A. Kong, N. Sattar, 2018, Circulation.

A fall in portal vein insulin does not cause the alpha-cell response to mild, non-insulin-induced hypoglycemia in conscious dogs.

A. Cherrington, A. Powers, D. Neal, 2003, Metabolism: clinical and experimental.

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL

R. Holman, Adrian F. Hernandez, A. Maggioni, 2019, Diabetes Care.

Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus

D. Baltrukonis, S. Gustavson, S. M. Gustavson, 2011, Diabetes, obesity & metabolism.

Intraportal administration of neuropeptide Y and hepatic glucose metabolism.

A. Cherrington, D. Neal, M. Shiota, 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

A. Kalgutkar, J. Pfefferkorn, L. Di, 2015, Drug Metabolism and Disposition.

Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man.

A. Ertl, S. Raj, S. Davis, 2008, American journal of physiology. Endocrinology and metabolism.

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial

R. Holman, A. Gray, Adrian F. Hernandez, 2021, Diabetes research and clinical practice.

Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus

D. Baltrukonis, S. Gustavson, V. Somayaji, 2011, Diabetes, obesity & metabolism.

Intraportal administration of neuropeptide Y and hepatic glucose metabolism.

A. Cherrington, D. Neal, M. Shiota, 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.

B. Hirshberg, G. Preston, S. Gustavson, 2011, Diabetes research and clinical practice.